# US 2016/0250313 A1 · Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250313 A1
- Document ID: US20160250313A1
- Status: Published application
- Kind: A1
- Application number: 15/046,908
- Filed: 2016-02-18
- Published: 2016-09-01
- Earliest claimed: 2011-04-13
- Assignees: Glaxosmithkline Biologicals SA
- Applicants: Glaxosmithkline Biologicals S.A.
- Inventors: Normand BLAIS; Steve LABBE; Jan POOLMAN
- Web page: https://patentgrep.com/patent/US20160250313A1

## CPC

- C07K 14/285: from Pasteurellaceae (F), e.g. Haemophilus influenza
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/0011: {Cancer antigens}
- A61K 39/102: {Pasteurellales, e.g. Actinobacillus}, Pasteurella; Haemophilus
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 27/16: Otologicals
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/16: for influenza or rhinoviruses
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/543: {intranasal}
- A61K 2039/55544: {Bacterial toxins}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/575: {humoral response}
- A61K 2039/70: {Multivalent vaccine}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/21: containing a His-tag
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C07K 2319/50: containing protease site
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to compositions comprising Haemophilus influenzae Protein E and Pilin A. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising Protein E and PilA, vaccines comprising such immunogenic compositions and therapeutic uses of the same.

## Claims

### Claim 1

A method for the treatment of otitis media caused wholly or in part by non-typeable Haemophilus influenzae in a subject in need thereof comprising administering to said subject a therapeutically effective amount of an immunogenic composition comprising the fusion protein of SEQ ID NO. 177
(QIQKAEQN DVKLAPPTDV RSGYIRLVKN VNYYIDSESI
WVDNQEPQIV HFDAVVNLDK GLYVYPEPKR YARSVRQYKI
LNCANYHLTQ VRTDFYDEFW GQGLRAAPKK QKKHTLSLTP
DTTLYNAAQI ICANYGEAFS VDKKGGTKKA AVSELLQASA
PYKADVELCV YSTNETTNCT GGKNGIAADI TTAKGYVKSV
TTSNGAITVK GDGTLANMEY ILQATGNAAT GVTWTTTCKG
TDASLFPANF CGSVTQ).

### Claim 2

A method for the treatment of otitis media caused wholly or in part by non-typeable Haemophilus influenzae in a subject in need thereof comprising administering to said subject a therapeutically effective amount of an immunogenic composition comprising the fusion protein of SEQ ID NO. 219
(IQKAEQND VKLAPPTDVR SGYIRLVKNV NYYIDSESIW
VDNQEPQIVH FDAVVNLDKG LYVYPEPKRY ARSVRQYKIL
NCANYHLTQV RTDFYDEFWG QGLRAAPKKQ KKHTLSLTPD
TTLYNAAQII CANYGEAFSV DKKGGTKKAA VSELLQASAP
YKADVELCVY STNETTNCTG GKNGIAADIT TAKGYVKSVT
TSNGAITVKG DGTLANMEYI LQATGNAATG VTWTTTCKGT
DASLFPANFC GSVTQ).

### Claim 3

A method for the treatment of pneumonia caused wholly or in part by non-typeable Haemophilus influenzae in a subject in need thereof comprising administering to said subject a therapeutically effective amount of an immunogenic composition comprising the fusion protein of SEQ ID NO. 177
(QIQKAEQN DVKLAPPTDV RSGYIRLVKN VNYYIDSESI
WVDNQEPQIV HFDAVVNLDK GLYVYPEPKR YARSVRQYKI
LNCANYHLTQ VRTDFYDEFW GQGLRAAPKK QKKHTLSLTP
DTTLYNAAQI ICANYGEAFS VDKKGGTKKA AVSELLQASA
PYKADVELCV YSTNETTNCT GGKNGIAADI TTAKGYVKSV
TTSNGAITVK GDGTLANMEY ILQATGNAAT GVTWTTTCKG
TDASLFPANF CGSVTQ).

### Claim 4

A method for the treatment of pneumonia caused wholly or in part by non-typeable Haemophilus influenzae in a subject in need thereof comprising administering to said subject a therapeutically effective amount of an immunogenic composition comprising the fusion protein of SEQ ID NO. 219
(IQKAEQND VKLAPPTDVR SGYIRLVKNV NYYIDSESIW
VDNQEPQIVH FDAVVNLDKG LYVYPEPKRY ARSVRQYKIL
NCANYHLTQV RTDFYDEFWG QGLRAAPKKQ KKHTLSLTPD
TTLYNAAQII CANYGEAFSV DKKGGTKKAA VSELLQASAP
YKADVELCVY STNETTNCTG GKNGIAADIT TAKGYVKSVT
TSNGAITVKG DGTLANMEYI LQATGNAATG VTWTTTCKGT
DASLFPANFC GSVTQ).

### Claim 5

A method for the treatment of a H. influenzae infection or disease in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of an immunogenic composition comprising the fusion protein of SEQ ID NO. 177
(QIQKAEQN DVKLAPPTDV RSGYIRLVKN VNYYIDSESI
WVDNQEPQIV HFDAVVNLDK GLYVYPEPKR YARSVRQYKI
LNCANYHLTQ VRTDFYDEFW GQGLRAAPKK QKKHTLSLTP
DTTLYNAAQI ICANYGEAFS VDKKGGTKKA AVSELLQASA
PYKADVELCV YSTNETTNCT GGKNGIAADI TTAKGYVKSV
TTSNGAITVK GDGTLANMEY ILQATGNAAT GVTWTTTCKG
TDASLFPANF CGSVTQ).

### Claim 6

A method for the treatment of a H. influenzae infection or disease in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of an immunogenic composition comprising the fusion protein of SEQ ID NO. 219
(IQKAEQND VKLAPPTDVR SGYIRLVKNV NYYIDSESIW
VDNQEPQIVH FDAVVNLDKG LYVYPEPKRY ARSVRQYKIL
NCANYHLTQV RTDFYDEFWG QGLRAAPKKQ KKHTLSLTPD
TTLYNAAQII CANYGEAFSV DKKGGTKKAA VSELLQASAP
YKADVELCVY STNETTNCTG GKNGIAADIT TAKGYVKSVT
TSNGAITVKG DGTLANMEYI LQATGNAATG VTWTTTCKGT
DASLFPANFC GSVTQ).

### Claim 7 (depends on 7)

The method of claim 7, wherein the H. influenzae infection or disease is an NTHi infection or disease.

### Claim 8

A process for producing periplasmic expression of a fusion protein wherein the process comprises inducing expression of proteins containing a signal peptide wherein the fusion protein is the fusion protein of SEQ ID NO. 148 wherein the signal peptide has been removed, SEQ ID NO. 177
(QIQKAEQN DVKLAPPTDV RSGYIRLVKN VNYYIDSESI
WVDNQEPQIV HFDAVVNLDK GLYVYPEPKR YARSVRQYKI
LNCANYHLTQ VRTDFYDEFW GQGLRAAPKK QKKHTLSLTP
DTTLYNAAQI ICANYGEAFS VDKKGGTKKA AVSELLQASA
PYKADVELCV YSTNETTNCT GGKNGIAADI TTAKGYVKSV
TTSNGAITVK GDGTLANMEY ILQATGNAAT GVTWTTTCKG
TDASLFPANF CGSVTQ).

### Claim 9 (depends on 8)

The method of claim 8, wherein the H. influenzae infection or disease is an NTHi infection or disease.

### Claim 10

A process for producing periplasmic expression of a fusion protein wherein the process comprises inducing expression of proteins containing a signal peptide wherein the fusion protein is the fusion protein of SEQ ID NO. 194 wherein the signal peptide has been removed, SEQ ID NO. 219
(IQKAEQND VKLAPPTDVR SGYIRLVKNV NYYIDSESIW
VDNQEPQIVH FDAVVNLDKG LYVYPEPKRY ARSVRQYKIL
NCANYHLTQV RTDFYDEFWG QGLRAAPKKQ KKHTLSLTPD
TTLYNAAQII CANYGEAFSV DKKGGTKKAA VSELLQASAP
YKADVELCVY STNETTNCTG GKNGIAADIT TAKGYVKSVT
TSNGAITVKG DGTLANMEYI LQATGNAATG VTWTTTCKGT
DASLFPANFC GSVTQ).
